Teriflunomide Tablet, Film Coated
Product Images NDC 46708-314

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 46708-314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

28 Tablets (Teriflunomide Carton 14mg)

Teriflunomide Tablets 14 mg film-coated oral tablets packaging label by Alembic Pharmaceuticals Limited. The label indicates a package containing 28 tablets. The front and sides state the dose strength as 14 mg per tablet, with standard storage instructions and pharmacist dispensing advice. The label includes a barcode and manufacturer details from Gujarat, India.*

FDA Label Image

28 Tablets (Teriflunomide Carton 7mg)

Packaging label for Teriflunomide Tablets 7 mg, film-coated oral tablets. The label indicates a package size of 28 tablets. The product is labeled as prescription only and manufactured by Alembic Pharmaceuticals Limited. The label includes dosage strength, barcode, and storage instructions.*

FDA Label Image

Fig2 (Teriflunomide Fig2)

A Kaplan-Meier curve graph showing disability progression sustained for 12 weeks over time (in weeks) for placebo, 7 mg, and 14 mg Teriflunomide tablets. The vertical axis represents the percentage of patients with sustained progression, and the horizontal axis displays time up to 108 weeks. The graph includes a table listing the number of patients at risk per group at various time points. The 14 mg Teriflunomide group shows a statistically significant difference versus placebo (p < 0.05).*

FDA Label Image

Figure 1 (Teriflunomide Fige1)

A line graph displaying the percentage of disability progression sustained over 12 weeks in subjects taking Placebo, 7 mg Teriflunomide tablets, and 14 mg Teriflunomide tablets. The x-axis represents time in weeks (0 to 108), and the y-axis represents the percentage of disability progression sustained. Numerical data for the number of subjects at risk is shown below the x-axis for each group at various time points.*

FDA Label Image

Structure (Teriflunomide Structure)

Chemical structure of Teriflunomide showing its molecular skeleton with key functional groups including trifluoromethyl, amide, nitrile, and hydroxyl groups.*

FDA Label Image

28 Tablets (Teriflunomide Wallet 14mg)

Packaging label for Teriflunomide Tablets 14 mg film-coated oral tablets by Alembic Pharmaceuticals Limited. The label displays blister pack design with push and peel tabs, dosage strength, NDC 46708-314-14, and instructions for dispensing the medication guide. Contains 28 tablets in total.*

FDA Label Image

28 Tablets (Teriflunomide Wallet 7mg)

Label for Teriflunomide Tablets 7 mg oral film-coated tablets by Alembic Pharmaceuticals Limited. The label includes the NDC 46708-313-14, package size of 28 tablets, and states Rx only. Blister pack illustrations and opening instructions are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.